Lead Selection & Optimization
Lead selection and optimization is a critical process in the identification of molecules that meet predefined requirements and can be progressed to the next step of development. While biologics lead selection mainly involves the screening of lead biological molecules to select those with desired functional and biophysical characteristics, optimization helps improve these properties.
Octet® BLI systems are improving the speed and efficiency of selection and optimization workflows with high throughput and easily developed assays for applications like affinity ranking, epitope binning of large antibody matrices, Fc-receptor binding, glycosylation screening, antibody-antigen specificity, binding characterization and titer analysis.
Titer and protein concentration determination is a critical process in the development of biologics drug molecules. The active protein concentration can be used to determine potency of the drug molecule. Titer and protein concentration determination are more robust to cell culture and media, making them desirable as replacement for enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography (HPLC) in upstream and downstream processes.
Read Application Note
In early drug development, cross-competition studies are necessary to characterize hundreds of antibody clones. Since monoclonal antibodies in different bins bind to distinct antigen epitopes and display diverse functional characteristics, epitope binning studies can increase the likelihood of choosing a lead antibody with the desired biological activity.
Epitope binning studies rely on the sequential binding of two antibodies to an antigen, and are performed using dozens of antibody pairs in cross-competition matrices. The Octet® BLI platform excels at these large-scale studies due to assay speed, throughput and exceptional reproducibility.
When screening crude samples with unknown concentrations, off-rate screening is a powerful tool for predicting sample properties. Library screening by ELISA does not enable ranking of antibodies based upon their affinities for an antigen. Using Octet® BLI systems, clones with high affinities and low off-rates can be rapidly identified and selected for further characterization. Many biotechnology companies utilize the technology in automated affinity screening and off-rate screening of positive clones obtained from ELISA-based primary screens.
Read More
Monitoring the binding of candidate molecules to targets is a critical process in lead molecule selection and can aid in the selection of desirable clones. Octet® BLI systems generate highly-precise data on molecular binding affinities, specificities and association/dissociation rate constants and in a high throughput manner.
Fragment-based drug design (FBDD) has become an increasingly popular platform for the identification of lead candidates in drug discovery programs. The detection and characterization of fragment binding events is facilitated by sensitive biophysical technologies capable of detecting low affinity interactions of low molecular weight compounds. The Octet® SF3 system has the necessary sensitivity and throughput to provide complete fragment screens on libraries of several thousand compounds in just a few weeks per target.
Boost your research and commercialization goals by combining BLI and SPR at an attractive promotional price.
Drug development and production is challenging. Avitide, based in Lebanon, New Hampshire, provides on-demand development and supply of high-performanc...
A comprehensive guide for designing and performing assays that accurately measure the binding kinetics of biomolecular interactions and analyte concen...
Improve the overall drug discovery process to increase the success rate of preclinical candidates
Using Octet® SAX Biosensors
Rapid quantitative screening of bispecific antibodies using Protein A and HIS1K biosensors
By Octet® Bio-Layer Interferometry (BLI) Platforms
For Accurate Determination of Kinetics and Affinity Rate Constants
Antibody and other protein therapeutics are a major focus in drug discovery pipelines today
Accelerating Antibody Discovery by Monitoring Titer and Glycosylation With the Octet® Platform
Generate high-quality kinetics and affinity data in a fraction of the time compared to standard multi-cycle kinetics using the Octet® SF3.
Monitors up to 96 biosensors simultaneously, enabling label-free detection for protein quantitation and kinetic characterization at unmatched speed
Ideal for high-throughput applications that demand high sensitivity and low sample volume requirements
Unmatched flexibility and versatility in protein analysis
Get the Latest Updates, Trends and Developments on Label-free, Stress-Free Solutions for Drug Discovery, Biologics Development and Biomanufacturing.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.